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Abstract
BRIP1 is a moderate susceptibility epithelial ovarian cancer (EOC) gene. Having identified
the BRIP1 c.1045G>C missense variant in a number of families with EOC, we aimed to
investigate the frequency of this and BRIP1.2392C>T pathogenic variant in patients with
breast cancer (BC) and/or EOC. A case-control study of 3767 cases and 2043 controls was
undertaken investigating the presence of these variants using Sanger sequencing and gene
panel data. Individuals with BC and/or EOC were grouped by family history. BRIP1
c.1045G>C was associated with increased risk of BC/EOC (OR = 37.7; 95% CI 5.3–444.2;
P = 0.0001). The risk was highest for women with EOC (OR = 140.8; 95% CI 23.5–
1723.0; P < 0.0001) and lower for BC (OR = 11.1; 95% CI 1.2–106.5; P = 0.1588). BRIP1
c.2392C>T was associated with smaller risks for BC/EOC (OR = 5.4; 95%CI 2.4–12.7;
P = 0.0003), EOC (OR = 5.9; 95% CI 1.3–23.0; p = 0.0550) and BC (OR = 5.3; 95%CI
2.3–12.9; P = 0.0009). Our study highlights the importance of BRIP1 as an EOC
susceptibility gene, especially in familial EOC. The variant BRIP1 c.1045G>C, rs149364097,
is of particular interest as its dominant-negative effect may confer a higher risk of EOC
than that of the previously reported BRIP1 c.2392C>T nonsense variant. Dominant-
negative missense variants may confer higher risks than their loss-of-function counterparts.
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1 | INTRODUCTION
Epithelial ovarian cancer (EOC) is a highly heritable cancer, with a three-
fold increase in risk for first-degree relatives of affected women.1
Approximately 10–15% of EOC is considered to be hereditary. This is
somewhat higher in the most common high grade serous (HGSOC) sub-
type, although the precise figure is unknown.1–4 For many years BC and
EOC have been noted to affect multiple individuals in some families,5
leading to the identification of hereditary breast and ovarian cancer syn-
drome (HBOC). Pathogenic variants (PVs) in BRCA1 and BRCA2 explain
approximately 25% of HBOC, and PVs in other genes in homologous
recombination, mismatch repair and cell cycle checkpoint pathways
account for additional significant contributions to risk.6,7 However, the
cause of approximately 35% of familial EOC remains unexplained.
The gene BRCA1 interacting protein 1 (BRIP1) encodes the protein
BRIP1, which interacts with BRCA1 through BRCT repeats at the
c-terminal end of BRCA1 and is required for normal repair of double-
strand DNA breaks.8 PVs have been found in the first two-thirds of
the gene, between nucleotides 68–2508, predicted to truncate the
protein before the BRCA1 binding domain.9 The gene is part of the
Fanconi anaemia complement group family of proteins and is also
known as FANCJ and BACH1.10
BRIP1 was originally considered to be a BC susceptibility gene in
2006 by Seal et al.11 with identification of truncating PVs in BRIP1 in nine
of 1212 women with BC, but in only two of 2081 controls (p = 0.003),
conferring an estimated relative risk (RR) of 2.0. All women with breast
cancer had a family history of BC and/or EOC. The most common PV
found was the truncating variant BRIP1 c.2392C>T; p.(Arg798Ter) in exon
17, occurring in five affected women and one of the controls.11 BRIP1 PVs
were further reported in subsequent studies,12–14 including one15 that
genotyped the BRIP1 c.2392C>T; p.(Arg798Ter) variant and 10 missense
variants in >48 000 affected individuals and 43 000 controls from the
Breast Cancer Association Consortium (BCAC). The coding regions in
>16 000 affected individuals and >8000 controls were also sequenced and
there was some weak evidence of an association between BRIP1
c.2392C>T; (p.Arg798Ter) and ER-negative and triple-negative disease.
However, overall there was no significant association between BRIP1 and
BC risk.15 Conflicting or no significant evidence of BRIP1 as a BC risk gene
was confirmed in further studies,16,17 but the most definitive evidence
from over 60 000 women with BC suggests there is no association.18
BRIP1 is now considered more significant in conferring risk
for EOC. An Icelandic study found a frameshift variant, BRIP1
c.2040_2041insTT increased EOC risk with an odds ratio (OR) of
8.13, and carriers of the variant with an average 3.6 years shorter life
expectancy than non-carriers.19 A study of germline variants in genes
associated with EOC from 1915 women with EOC compared PV
frequencies with women from the NHLBI GO Exome Sequencing
Project (ESP) and the Exome Aggregation Consortium (ExAC) and
found ORs of 9.1 compared to ESP controls and 6.4 compared to
ExAC controls.20 In a 2017 study, standardised RR for BRIP1 and EOC
of 4.99 was calculated from 7768 EOC patients of European ancestry.21
In a 2018 case-control study BRIP1 loss of function PVs were described
to confer a high risk of OC in women with a strong family history of OC
(OR = 20.97; OR for late-onset OC = 29.91).16 Overall, BRIP1 PV
carriers seem to develop EOC at the same age as in the general
population, and have an estimated 5.8% cumulative lifetime risk.9,22 A
recent meta-analysis by Suszynska et al. including 22 494 EOC cases
found BRIP1 to have an OR of 4.94 (95% 4.07–6.00; P < 0.0001).23
In 2019 three unrelated women with familial non-mucinous EOC
ascertained through the Manchester Centre of Genomic Medicine
(MCGM) were found to carry the missense variant BRIP1 c.1045G>C;
p.(Ala349Pro), (rs149364097). This variant is described as pathogenic/
likely pathogenic in ClinVar.24 We hypothesised that this variant may
be enriched in our patient population as an EOC and/or BC PV. We
aimed to investigate the frequency of this variant as well as the
established BRIP1 c.2392C>T variant through a case-control study.
2 | MATERIALS AND METHODS
2.1 | Study design and participants
Women were recruited through the ‘Investigation of genetic modifiers in
BRCA1/2 breast cancer and non BRCA1/2 high risk families’ study for
whole exome sequencing and Sanger sequencing at MCGM, the
Predicting Risk of Cancer at Screening (PROCAS) study and FH-Risk.25
Five hundred and twenty-one women from our centre had been
included in the study by Seal et al.11 and as such had had DNA analysed
for variant BRIP1 c.2392C>T; p.(Arg798Ter). The primary source of par-
ticipants included in our study is summarised in Table 1.
The PROCAS study recruited women aged 46–73 years attending
BC screening in Greater Manchester, who were not affected with
either BC or EOC at study entry. Women who developed BC after
entry were included as cases.25 Their samples underwent panel testing
as part of the Breast Cancer Risk after Diagnostic Gene Sequencing
(BRIDGES) study.18 Women who were recruited to the Predicting Risk
of Cancer at Screening (PROCAS) study with no BC diagnosis were
included as controls; this meant that the controls would be from the
same geographical region as the cases and similarly known to MCGM.
Cases comprised all women with non-mucinous EOC or BC, aged
18 years or over known to MCGM. They were recruited 1990–2020,
but the ovarian cancer cases predominantly from 2016. Controls were
women with no history of EOC or BC and no prior known PVs. They
were recruited through PROCAS 2009–2013, and cancer-free as of
2020. Controls (group 1) were compared with cases in five groups:
women with BC and no family history of EOC (group 2), women with BC
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and a family history of EOC (group 3), women with EOC and no BC/EOC
family history (group 4), women with EOC and family history of BC only
(group 5), and women with familial EOC (≥2 family members) (group 6).
2.2 | Data extraction
Relevant clinical information (histology of EOC and BC diagnoses,
age at diagnosis, family history of BC and/or EOC) was obtained
from local clinical record systems. Data for PROCAS patients was
obtained from a questionnaire completed at study entry. Prospec-
tive cancer diagnoses were updated through the cancer registry.
2.3 | DNA extraction
DNA was extracted from peripheral blood lymphocytes from women
who attended MCGM with EOC and ≥2 affected relatives with EOC.
DNA from the women in PROCAS was extracted from saliva using an
Oragene kit (DNA Genotek) according to the manufacturer's protocols.
2.4 | Sanger sequencing
Amplification of exon 8 of BRIP1 to genotype c.1045G>C was done
by using the following forward and reverse primers: 50-GTGG
CTTTAATGATGTTCCTC-30 and 50-CTCACACTTTCCCTTATTT
GTG-30 , respectively. Similarly, amplification of a 702 bp region
was used to screen exon 17 of BRIP1 for the truncation PV
c.2392C>T; p.(Arg798Ter). Sequences for the forward and reverse
primers were: 50-GTAATTTAAGGAATGTGAAGC-30 and 50-GAGC
ATCTTTGTGTGCTATTC-30. The amplified fragments were then
visualised using gel electrophoresis, purified, and sequencing reac-
tions were prepared using the BigDye™ Terminator v3.1 Cycle
Sequencing kit (Thermo Fisher Scientific Inc., Waltham, MA).
Sequencing reactions were analysed using an ABI3730xl DNA
Analyser (Life Technologies, Paisley, UK).
2.5 | Statistical methods
Data was combined from the patients included in the panel screening,
the patients included in the Seal et al.11 patients included in PROCAS-
BRIDGES, those who had undergone exome sequencing and those on
whom we performed Sanger sequencing for these two variants. Dupli-
cates, cases who had undergone panel screening which did not
include BRIP1, and cases with inappropriate histology/diagnosis or
absent cancer information were removed.
We examined the ORs for the case–control study grouped in five
ways1: all cases (groups 2–6)2; all EOC cases (groups 4–6)3; BC cases
(groups 2 and 3)4; family history of EOC (groups 4 and 6); and5 women
with BC only. In all OR estimations data from gnomAD v.2.1.1 for each
variant (controls, European non-Finnish population26) was used for the
control value as no PVs were detected in our control group.
Odds ratios were calculated using GraphPad Prism 8.4.3 and 95% con-
fidence intervals and two-sided p-values using the Baptista-Pike method
and Fisher's exact test. P-value was considered significant at 0.05.
The STROBE case-control checklist was used to present the data.27
TABLE 1 Table of sources of study participants genotyped for BRIP1 c.1045G>C and BRIP1 c.2392C>T pathogenic variants







PROCAS/BRIDGES studies (controls) 2566 2566 2566
Sanger sequencing at MCGM (cases) 2172 2172 2162
BC cases 1551 1551 1550
EOC cases 698 698 688
Cancer panels (cases) 365 365 365
BC cases 350 350 350
EOC cases 17 17 17
FH-risk (cases) 207 197 207
BC cases 206 196 206
EOC cases 2 2 2
Seal et al. study (cases) 500 0 500
BC cases 500 N/A 500
EOC cases 0 N/A 0
Total 5810 5300 5800
Cases 3244 2734 3234
Controls 2566 2566 2566
aWhere participants were included in multiple categories (for example cancer panels and the Seal et al. study) the source with the most genetic information
has been listed as the primary source.
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3 | RESULTS
3.1 | Patient demographics
A total of 3767 individuals with BC and/or EOC and 2043 controls were
tested for the two variants. These are described further in Table 2.
3.2 | BRIP1 c.1045G>C frequency
Cases and controls were categorised by diagnosis and relevant family
history, as shown in Table 3. Four out of six individuals with this vari-
ant had EOC. Three of these were in group 6 and had HGSOC, and
one patient was in group 5 and was diagnosed with poorly differenti-
ated ovarian adenocarcinoma at 60 years and ER-positive
HER2-negative ductal BC at 63 years. They were all white British; the
mean age at EOC diagnosis 62.5 (range 51–71) years. Two women
with BC in group 2 recruited from PROCAS had this PV; one woman
also had a BRCA2 PV and was subsequently removed from analysis as
this was presumed to be the disease associated PV in this case. The
remaining woman was diagnosed with intermediate grade, ER-posi-
tive, HER2-negative ductal carcinoma in-situ at 61 years.
The variant was not detected in the control group. Therefore,
ORs for the missense PV BRIP1 c.1045G>C were calculated using
control frequencies from the gnomAD v2.1.1 control data using the
European non-Finnish population to be as representative of our study
population as possible26 (allele frequency 1/48286 = 0.00002071; 1/
24143 women).
The PV BRIP1 c.1045G>C was associated with increased risk of
BC/EOC in groups 2–6 (OR = 37.7; 95% CI 5.3–444.2; P = 0.0001).
The risk was especially strong for women with EOC (groups 4–6)
(OR = 140.8; 95% CI 23.5–1723.0; P < 0.0001) and maintained in
women with a diagnosis and family history exclusively of EOC (groups
4 and 6) (OR = 139.3; 95% CI 20.7–1809.0; P < 0.0001).









EOC and BC (n) 73





EOC and BC (n) 74
Epithelial ovarian cancer
Total with EOC diagnosis (n) 717
Mean age at diagnosis (range) 57 (20–83)
HGSOC (%) 556 (77.5)
Breast cancer
Total with BC diagnosis (n) 3129
Mean age at diagnosis (range) 46 (15–90)
ER positivea (%) 1133/2062 (54.9)
HER2 positivea (%) 178/1124 (15.8)
TNBCa (%) 348/1120 (31.0)
MBC (%) 34 (1.1)
Abbreviations: EOC, epithelial ovarian cancer; BC, breast cancer; HGSOC,
high grade serous ovarian cancer; ER, Estrogen receptor; HER2, human
epidermal growth factor receptor 2; TNBC, triple negative breast cancer;
MBC, male breast cancer.
aWhere data available.














1 (controls) 2043 0 0.00 2043 0 0.00
2 2180 1 0.05 2655 6 0.23
3 339 0 0.00 363 2 0.55
4 430 0 0.00 423 1 0.24
5 167 1 0.60 174 1 0.57
6 93 3 3.23 85 0 0.00
All cases (2–6) 3209 5 0.16 3700 10 0.27
gnomADa 24 143 1 0.00 23 901 12 0.00
Note: Group 1 – Controls; Group 2 – Breast cancer diagnosis only, no family history of ovarian cancer. Group 3 – Breast cancer diagnosis only, positive
family history of ovarian cancer. Group 4 – Ovarian cancer diagnosis, no family history of breast cancer. Group 5 – Ovarian cancer diagnosis, positive
family history of breast cancer only. Group 6 – Ovarian cancer diagnosis, strong family history of ovarian cancer (≥2 family members).
aControls, European, non-Finnish population.
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The risk was not significant for BC (groups 2 and 3) (OR = 9.6;
95% CI 0.5–182.2; P = 0.18) or in individuals with BC only and no
family history of EOC (group 2) (OR = 11.1; 95% CI 1.2–106.5;
P = 0.1588).
3.3 | BRIP1 c.2392C>T frequency
A breakdown of results by group is shown in Table 3. Of the 10 indi-
viduals carrying this variant, eight had BC, one had EOC and one had
BC and EOC. All white British, of the individuals with BC the mean
age at diagnosis was 44 (range 30–74) years, eight had infiltrating
ductal carcinoma and two had lobular carcinoma. Three women had
ER-positive disease, four ER-negative and in two the ER status was
unknown. Six had HER2-negative disease and in the other three
HER2 status was unknown; four women had triple negative disease.
The two women with an EOC diagnosis had HGSOC and were diag-
nosed at 59 and 60 years.
As there was no frequency for stop-gain PV BRIP1 c.2392C>T in
local controls, ORs were calculated using control frequencies from the
European non-Finnish gnomAD v2.1.1 population (allele frequency
for: 12/47 802 alleles = 0.0002510, 12/23 901 women). The PV
BRIP1 c.2392C>T was associated with a significant, but much weaker
risk of BC /EOC in groups 2–6 (OR = 5.4; 95%CI 2.4–12.7;
P = 0.0003). This risk was close to signficance in all women with EOC
(groups 4–6) (OR = 5.9; 95% CI 1.3–23.0; p = 0.0550) and not signifi-
cant for women with a diagnosis and family history exclusively of
EOC (groups 4 and 6) (OR = 3.9; 95% CI 0.4–24.6; P = 0.2393).
The variant was associated with significant risk of BC in all BC
groups 2 and 3 (OR = 5.3; 95%CI 2.3–12.9; P = 0.0009) and in indi-
viduals with BC and no family history of EOC (group 2) (OR = 4.5;
95%CI 1.8–11.3; p = 0.0064).
4 | DISCUSSION
Our study highlights the importance of BRIP1 as an EOC susceptibility
gene, in particular in familial EOC cases. The BRIP1 c.1045G>C PV
was present in 3.23% of our cases with familial EOC. The finding of
this variant in this population is of particular interest and it may be
that this variant is more common in North-West of England as it has
not been described as significantly in other studies. Although to the
best of our knowledge our BRIP1 c.1045G>C PV carriers are
unrelated, it is possible that they could link several generations before.
As the majority of the data were generated through Sanger sequenc-
ing for these specific variants, insufficient data were available for
haplotype analysis. No samples were available from other affected
family members to perform segregation analysis.
This variant seems extremely relevant to EOC risk, and not signifi-
cantly for BC. The meta-analysis by Suszynska et al. found the BRIP1
c.2392C>T present in 14/22 494 (0.06%) cases, compared to
37/131 983 (0.03%) controls with an associated OR of 2.22 (95% CI
1.20–4.11; P = 0.011). There was one BRIP1 c.1045G>C (1/22 494;
0.0044%) variant in the affected individuals and 4 out of 134 094
controls (0.003%).23 The affected individual was reported in an Ameri-
can study of 4439 women with EOC (74.8% Caucasian origin).28 The
BRIP1 c.1045G>C variant has been reported in individuals with Fan-
coni anaemia in three studies10,29,30 as well as in individuals with
EOC31 and BC.15 However the frequency of this variant in individuals
with BC /EOC is scarce and multiple affected individuals have not
been reported before.
In a previous study, the variant was noted to be immediately adja-
cent to a highly conserved cysteine of the iron-sulphur domain. This
Fe-S domain is important in DNA repair proteins from structural and
functional studies.29 The p.Arg349Pro BRIP1 differed from wild-type
BRIP1 by possessing only one iron atom per polypeptide compared to
three for wild-type; had no DNA helicase activity; disrupted protein-
DNA interactions, and exerted a dominant-negative effect on cell sur-
vival or DNA damage accumulation following cisplatin or telomestatin
treatment.29
Overall these biochemical and cellular function studies provide
supporting evidence for the theory this variant affects DNA damage
repair and therefore could be an EOC susceptibility PV, similar to
those in other homologous recombination genes. This would have
potential treatment implications in terms of patients with this variant
being likely to respond to PARP inhibitors.32
Of clinical significance, PVs in BRIP1 have been demonstrated to
make cells very sensitive to cisplatin, a DNA-crosslinking agent.33 It
follows that patients with pathogenic BRIP1 variants may be more
likely to have platinum-sensitive EOC and treatment could be planned
accordingly. As a gene involved in homologous recombination it may
also be the case that patients with BRIP1 PVs would be highly sensi-
tive to treatment with poly-ADP ribose polymerase (PARP) inhibitors,
as is the situation for women carrying BRCA1/2 PVs.
The dominant-negative nature of some missense variants has
been shown to increase the risk of associated cancer with some other
genes. Notably the ATM missense variant c.7271T>G (p.Val2424Gly)
has been shown to confer a high risk of BC (>50% lifetime risk)
compared to the more moderate 2–3 fold relative risk (lifetime risk
20–30%) associated with ATM loss of function variants [28]. The same
genotype–phenotype effect has been reported for dominant-negative
TP53 missense variants in Li Fraumeni syndrome.29 The nature of
these dominant-negative variants is that the abnormal protein inter-
feres with function of wild type by dimerization or tetramerization
thus reducing the availability of wild type protein even below the
50% associated with loss of function variants. In the case of BRIP1
c.1045G>C, this is associated with a far higher risk of EOC than the
loss of function BRIP1 c.2392C>T variant.
This is demonstrated particularly by the presence of such a high
frequency in the women with familial EOC. The situation with mis-
sense variants in ATM, TP53 and now BRIP1 is different to the weaker
effects of missense variants in genes like CHEK2, where loss of func-
tion variants confer a higher risk, than missense variants.30
The BRIP1 c.2392C>T PV showed a significant increase of risk for
BC and a significant but smaller risk for the combined group in our
study. We had a detection rate for this variant of 10/3700 (0.27%),
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five times higher assuming the same OR than the detection rate of
0.047% in the Easton et al study.15 As we found an OR of 5 for BC
and this was not found in the Easton study there may be another fac-
tor such as a potential founder effect contributing, or our ORs are
incorrect and a more accurate OR for this variant would be a fifth of
what we found. We did nonetheless not find this variant in over 2000
controls meaning a local population rate below 0.05%. It is possible
therefore the truth lies in between.
There are some limitations to the present study. Both BRIP1 vari-
ants may be local founders and the true odds ratios of their effects
may be lower. Nevertheless, we did not find either variant in over
2000 control samples and the larger gnomAD control dataset,
restricted to the European non-Finnish population, was the best alter-
native. Even still the EOC conferred by the nonsense variant BRIP1
c.2392C>T is similar to previous estimates.
While this needs further validation, the dominant-negative effect
of the BRIP1 c.1045G>C variant is likely to mean a more significant
EOC risk than that of the well-known stop-gain BRIP1 c.2392C>T var-
iant. Although rarer, due to the dominant-negative effect it has, it
appears to confer a higher risk of EOC and should be considered in
investigation of women with familial EOC. Finally, clinicians should
not assume that a missense variant that is classified as pathogenic or
likely pathogenic confers the same risk as loss of function variants. In
particular, an assessment of whether the variant may be associated
with a dominant-negative effect is important.
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